ASAN vs PTRN

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score, limiting distress risk assessment. Despite strong gross margins and accelerating revenue and earnings growth, the company remains deeply unprofitable with negative ROE and ROA, high valuation multiples, and deteriorating insider sentiment. Aggressive insider selling, a bearish technical trend, and a significant disconnect between current price and analyst target further weigh on the outlook. While earnings surprises have been consistently positive, the overall risk profile remains elevated in a high-valuation, low-profitability context.

PTRN presents a stark contrast between strong growth metrics and poor operational health, as evidenced by a weak Piotroski F-Score of 2/9. While the company exhibits impressive YoY revenue growth of 40.30% and a reasonable Forward P/E of 23.01, its net profit margins are razor-thin at 0.65%. The balance sheet is clean with very low debt (D/E 0.05) and strong liquidity (Current Ratio 2.34), but the lack of operational efficiency drags down the deterministic health scores. The stock is currently viewed as a speculative growth play with a significant gap between its current price and analyst targets.